The Phoenix Stem Cell Treatment Center, USA
Title: The safety and apparent clinical efficacy of autologous, adipose derived SVF as a biological surgical tool in a variety of injuries, illnesses, and conditions
Steven Gitt, MD, FACS, graduated college at UCLA and medical school at Wayne State University. He completed his General Surgery residency at Good Samaritan Hospital in Phoenix, Arizona and his Plastic Surgery Residency at the University of Michigan Hospitals in Ann Arbor. Dr. Gitt is a Clinical Assistant Professor of Plastic Surgery at the University of Arizona, Phoenix School of Medicine and holds faculty appointments at several other medical schools. He is the founder and Medical director of North Valley Plastic Surgery and The Phoenix Stem Cell Treatment center. Dr. Gitt is on the editorial advisory boards of several scientific publications. He has spoken at both national and international meetings on a variety of topics and is a clinical researcher for RTI, inc., Ulthera Inc., Cynosure/Palomar inc., and Medi Khan, inc.. Dr. Gitt is a clinical spokesperson for Allergan inc., Ulthera inc., RTI inc., and Cynosure/Palomar inc.. He has spoken on Stem Cell/SVF/Regenerative medicine topics dozens of times.
Regenerative medicine promotes the repair or replacement of lost tissue or organ function due to damage or congenital defects, thereby creating living, functional tissues, and/or stimulating previously irreparable organs to heal themselves. Bone Marrow and embryonic stem cell therapies have presented great difficulties while autologous SVF is readily bioavailable, easily harvested, processed in a closed surgical setting with only minimal manipulation, and can be immediately utilized. Patients presented with a variety of orthopedic (peripheral and spinal), rheumatologic, neurologic, cardio-pulmonary, autoimmune, genitourinary, ophthalmic, gastrointestinal, degenerative, and deteriorative conditions. Nearly all patients received intravenous deployment, while intra-articular, intra-lesional, nebulized pulmonary, and direct injection (with radiologic guidance as needed) techniques were employed as dictated by protocols. Clinical efficacy showed that between 60%-80% of patients enjoyed positive responses. Global complication rate (generally minor incidents related to the liposuction required) was below 2% and there were NO serious or major adverse events. Our results show that this procedure is extremely safe, ethical, versatile and appears to have a consistently high efficacy and therapeutic yield.